VYNE Therapeutics (VYNE) News Today $0.30 -0.01 (-1.87%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$0.32 +0.01 (+3.88%) As of 09/19/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VYNE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period VYNE Therapeutics Faces Nasdaq Non-Compliance NoticeSeptember 12, 2025 | msn.comVYNE Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues LagAugust 19, 2025 | finance.yahoo.comVitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightAugust 14, 2025 | finance.yahoo.comVYNE Therapeutics reports Q2 EPS (13c) vs (22c) last yearAugust 14, 2025 | msn.comVYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business UpdateAugust 14, 2025 | globenewswire.comVitiligo Pipeline Outlook Report 2025: Key 18+ Companies and Breakthrough Therapies Shaping the Future LandscapeAugust 5, 2025 | theglobeandmail.comHere's Why VYNE Therapeutics (NASDAQ:VYNE) Must Use Its Cash WiselyAugust 1, 2025 | finance.yahoo.comVyne Therapeutics Ends Trial of Repibresib Gel in Nonsegmental VitiligoJuly 31, 2025 | marketwatch.comVYNE Therapeutics stock falls after vitiligo trial fails to meet endpointsJuly 31, 2025 | za.investing.comHC Wainwright & Co. Downgrades VYNE Therapeutics (VYNE)July 31, 2025 | msn.comVYNE Therapeutics Shares Sink Premarket Following End to Trial After Endpoint MissedJuly 31, 2025 | marketwatch.comVyne Hit With Downgrades After Repibresib Misses Endpoints In Vitiligo Trial; Traders Still Eye ReboundJuly 31, 2025 | msn.comVYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental VitiligoJuly 30, 2025 | globenewswire.comVyne Therapeutics: A Risky Bet On Upcoming Vitiligo Ph2b ReadoutJuly 28, 2025 | seekingalpha.comVYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline ProgressJuly 11, 2025 | insidermonkey.comVYNE Therapeutics Provides Update on VYN202 Program Following FDA Clinical Hold for Psoriasis TrialJuly 2, 2025 | quiverquant.comQVYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202July 2, 2025 | globenewswire.comVYNE Stock Touches 52-Week Low at $0.96 Amid Market ChallengesMay 31, 2025 | investing.comVYNE Therapeutics First Quarter 2025 Earnings: Beats ExpectationsMay 12, 2025 | finance.yahoo.comVYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comVYNE Therapeutics' Psoriasis Drug Trial Halted By FDA Over Toxicity Concerns; Stock Down.April 27, 2025 | nasdaq.comVYNE Therapeutics Inc. Faces FDA Clinical Hold on VYN202 Phase 1b Trial for Plaque PsoriasisApril 27, 2025 | nasdaq.comAnalysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and VYNE Therapeutics (VYNE)April 26, 2025 | markets.businessinsider.comVYNE Therapeutics Inc.: VYNE Therapeutics Provides Update on VYN202 ProgramApril 25, 2025 | finanznachrichten.deVYNE shares tumble after FDA clinical hold on psoriasis drug studyApril 25, 2025 | za.investing.comFDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On HoldApril 25, 2025 | benzinga.comVYNE Therapeutics Provides Update on VYN202 ProgramApril 25, 2025 | globenewswire.comArtiva Biotherapeutics, Inc.: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical OfficerApril 9, 2025 | finanznachrichten.deArtiva Biotherapeutics Names New Chief Medical OfficerApril 8, 2025 | marketwatch.comVYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2025 | markets.businessinsider.comVYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2025 | globenewswire.comH.C. Wainwright Sticks to Their Buy Rating for Lineage Therap (LCTX)March 11, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE), Lexicon Pharmaceuticals (LXRX) and Xtant Medical Holdings (XTNT)March 7, 2025 | markets.businessinsider.comVYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 7, 2025 | finance.yahoo.comVYNE Therapeutics reports Q4 EPS (28c) vs (20c) last yearMarch 6, 2025 | markets.businessinsider.comVYNE Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)March 6, 2025 | benzinga.comVYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business UpdateMarch 6, 2025 | globenewswire.comVYNE Therapeutics Inc.: VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque PsoriasisFebruary 20, 2025 | finanznachrichten.deTD Cowen Remains a Buy on VYNE Therapeutics (VYNE)February 20, 2025 | markets.businessinsider.comVyne doses first participant in Phase Ib plaque psoriasis treatment trialFebruary 20, 2025 | finance.yahoo.comVYNE Therapeutics to Participate in March Investor ConferencesFebruary 20, 2025 | globenewswire.comVYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque PsoriasisFebruary 19, 2025 | globenewswire.comAcne Vulgaris Therapeutics Market Size in the 7MM was ~USD 4,256 Million in 2023 and is projected to increase by 2034 | DelveInsightJanuary 24, 2025 | theglobeandmail.comPatrick G. Lepore Purchases 15,000 Shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) StockJanuary 17, 2025 | insidertrades.comVyne therapeutics director Patrick Lepore buys $43,800 in stockJanuary 16, 2025 | msn.comVYNE Therapeutics: Strategic Pipeline Advancements and Promising Clinical OutlookJanuary 14, 2025 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for VYNE Therapeutics (NASDAQ:VYNE)January 14, 2025 | marketbeat.comVYNE Therapeutics (VYNE) Gets a Buy from BTIGJanuary 8, 2025 | markets.businessinsider.comBuy Rating Justified for VYNE Therapeutics Due to Promising Repibresib Developments and Competitive AdvantagesJanuary 7, 2025 | markets.businessinsider.comVYNE Therapeutics completes enrolment in trial of gel for non-segmental vitiligoJanuary 7, 2025 | finance.yahoo.com Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VYNE Media Mentions By Week VYNE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VYNE News Sentiment▼0.000.78▲Average Medical News Sentiment VYNE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VYNE Articles This Week▼01▲VYNE Articles Average Week Get the Latest News and Ratings for VYNE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for VYNE Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies RVPH News Today KZR News Today DARE News Today CASI News Today TENX News Today RNTX News Today MIRA News Today LIXT News Today CVKD News Today AKTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VYNE) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
